Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (481-490 of 962) with videos related to

Pageof 97
Sort By:
European Heart Journal|August 10, 2014
Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trialWilliam Wijns, Ph Gabriel Steg, Laura Mauri, et al.
European Heart Journal. Acute Cardiovascular Care|November 14, 2013
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACSConnie N Hess, Phillip J Schulte, L Kristin Newby, et al.
American Heart Journal|May 13, 2015
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trialMichelle L O'Donoghue, Ruchira Glaser, Philip E Aylward, et al.
Journal of Thrombosis and Thrombolysis|May 31, 2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trialsDominick J Angiolillo, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology|March 26, 2024
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylMichael Szarek, Deepak L Bhatt, Michael Miller, et al.
American Heart Journal|May 17, 2011
Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromesSammy Ali, Shaun G Goodman, Raymond T Yan, et al.
International Journal of Cardiology|April 15, 2014
Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarctionChristopher Adlbrecht, Kurt Huber, Harmony R Reynolds, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 9, 2022
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trialMasafumi Ono, Hironori Hara, Hideyuki Kawashima, et al.
Drugs|June 21, 2020
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI TrialJosé C Nicolau, Deepak L Bhatt, Stefan H Hohnloser, et al.
American Heart Journal|March 27, 2007
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratificationGustavo B F Oliveira, Alvaro Avezum, Frederick A Anderson, et al.
Pageof 97

Showing results (481-490 of 962) with videos related to

Sort By:
Pageof 97
European Heart Journal|August 10, 2014
Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trialWilliam Wijns, Ph Gabriel Steg, Laura Mauri, et al.
European Heart Journal. Acute Cardiovascular Care|November 14, 2013
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACSConnie N Hess, Phillip J Schulte, L Kristin Newby, et al.
American Heart Journal|May 13, 2015
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trialMichelle L O'Donoghue, Ruchira Glaser, Philip E Aylward, et al.
Journal of Thrombosis and Thrombolysis|May 31, 2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trialsDominick J Angiolillo, Deepak L Bhatt, Ph Gabriel Steg, et al.
Journal of the American College of Cardiology|March 26, 2024
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylMichael Szarek, Deepak L Bhatt, Michael Miller, et al.
American Heart Journal|May 17, 2011
Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromesSammy Ali, Shaun G Goodman, Raymond T Yan, et al.
International Journal of Cardiology|April 15, 2014
Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarctionChristopher Adlbrecht, Kurt Huber, Harmony R Reynolds, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 9, 2022
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trialMasafumi Ono, Hironori Hara, Hideyuki Kawashima, et al.
Drugs|June 21, 2020
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI TrialJosé C Nicolau, Deepak L Bhatt, Stefan H Hohnloser, et al.
American Heart Journal|March 27, 2007
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratificationGustavo B F Oliveira, Alvaro Avezum, Frederick A Anderson, et al.
Pageof 97